2. UroToday Home
  3. Transformative Evidence
  4. The ARASENS Trial
  5. Articles
  6. Conferences

ESMO 2017

ESMO 2017

ESMO 2017: Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice

Madrid, Spain (UroToday.com) Dr. Flannery and colleagues presented their findings of second-line treatment patterns and outcomes of metastatic bladder cancer patients at ESMO 2017 poster session in Madrid, Spain. Currently, there is no universally accepted standard therapy for second-line treatment of metastatic bladder cancer. The objective of the study was to evaluate treatment patterns and outcomes of patients receiving second-line treatment for metastatic bladder cancer in real-world clinical practice.

ESMO 2017: Outcomes of patients with metastatic urothelial carcinoma with exclusive bone metastases: Focus on a special patient population

Madrid, Spain (UroToday.com) Patients with metastatic urothelial carcinoma with exclusive bone metastatic spread represent a rare subgroup of patients with unique clinical features. These patients deserve special consideration, as they are usually excluded from clinical trials due to the lack of measurable disease according to RECIST criteria. At today’s poster session at ESMO 2017, Dr. Andrea Necchi and colleagues focused on these patient’s access to treatment and outcomes.

ESMO 2017: Identification of genomic features underlying response of muscle-invasive bladder cancer to neoadjuvant sorafenib, gemcitabine, and cisplatin in an open-label, single-arm, phase 2 study

Madrid, Spain (UroToday.com) Dr. Daniele Raggi and colleagues presented results of a clinical study assessing genomic features of muscle invasive bladder cancer (MIBC) with regards to response to neoadjuvant chemotherapy at today’s ESMO 2017 poster session. Genomic analyses demonstrated that MIBC can be grouped into molecular subtypes that portend different outcomes with neoadjuvant chemotherapy (NAC).

ESMO 2017: Kidney Cancer Poster Discussion – Invited Discussant

Madrid, Spain (UroToday.com) Dr. Camillo Porta from Pavia, Italy provided an exceptional discussant presentation of four high-level renal cell carcinoma posters at today’s ESMO 2017 poster discussion symposium. The four posters discussed included “Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma” [1] by Dr. Toni Choueiri and colleagues, “IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma” [2] by Dr. Thomas Powles and colleagues, “Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases” [3] by Dr. Dominick Bosse and colleagues, and “Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial” [4] by Dr. Michael Staehler and colleagues.

ESMO 2017: Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

Madrid, Spain (UroToday.com) Dr. Andrea Necchi and international colleagues presented results assessing adjuvant chemotherapy after radical nephroureterectomy for upper tract urothelial carcinoma (UTUC) at today’s poster session at ESMO 2017 in Madrid, Spain. In patients with UTUC the benefit of adjuvant chemotherapy after radical nephroureterectomy is debated secondary to a lack of prospective randomized trials. The objective of this study was to assess the benefit of adjuvant chemotherapy vs observation in an international study.

ESMO 2017: Avelumab treatment of metastatic urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients

Madrid, Spain (UroToday.com) Dr. Andrea B. Apolo and colleagues presented updated analysis of avelumab for patients with metastatic urothelial carcinoma at today’s ESMO 2017 meeting in Madrid, Spain. Avelumab, a human anti–PD-L1 monoclonal antibody, has shown promising efficacy and safety in patients with metastatic urothelial carcinoma. The author’s objective for this study was to report an updated analysis of avelumab treatment in two cohorts of patients from JAVELIN Solid Tumor clinical trial [1].

ESMO 2017: Immunotherapy for Urothelial Cancer – Longer Follow-up and Subgroup Analyses: Invited Discussant

Madrid, Spain (UroToday.com) Dr. Maria De Santis provided an excellent discussant presentation for three urothelial cancer immunotherapy posters presented at ESMO 2017 in Madrid, Spain. The posters discussed included “Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial” [1] by Dr. Ronald De Wit and colleagues, “Subgroup Analyses from KEYNOTE-045: Pembrolizumab Versus Individual Investigator’s Choice of Chemotherapy (paclitaxel, docetaxel, or vinflunine) in Recurrent, Advanced Urothelial Cancer” [2] by Dr. Daniel Petrylak and colleagues, and “Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes from the Phase 2 IMvigor210 Study” [3] by Dr. Andrea Necchi and colleagues.

ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant

Madrid, Spain (UroToday.com) Dr. Ronald De Wit concluded the prostate cancer poster discussion session with an invited discussant presentation assessing four high-level abstracts presented at ESMO 2017 in Madrid, Spain. The four posters included “Safety and Immunogenicity of a DNA-vaccine Immunotherapy in Men with Biochemically (PSA) Relapsed Prostate Cancer” by Dr. Neal Shore, “Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer” by Dr. Diletta Di Mitri, “Phase I, Open-label, Dose-Finding Study of GSK2636771, a phosphoinositide 3-kinase β inhibitor, in Combination with Enzalutamide in Male Subjects with Metastatic Castration-Resistant Prostate Cancer” by Pasquale Rescigno and “Phase I study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer” by Dr. Michael Morris.

ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant

Madrid, Spain (UroToday.com) Dr. David Olmos from Madrid, Spain provided a discussion regarding two high-level posters at this morning’s prostate cancer session at ESMO 2017. The two studies included “DNA repair gene panel mutations in young onset and aggressive v non-aggressive prostate cancer cases in the UK” [1] by Dr. Eeles and colleagues and “Prognostic Associations of PSA Decline with Survival, Radiographic Response and Progression in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide” [2] by Dr. Armstrong and colleagues.

ESMO 2017: Urothelial Carcinoma Poster Discussion – Invited Discussant

Madrid, Spain (UroToday.com) Dr. Petros Grivas from the Cleveland Clinic provided the urothelial carcinoma invited discussant presentation this afternoon at the ESMO 2017 meeting in Madrid, Spain. Dr. Grivas discussed three excellent posters including “Comparison of tumor mutational burden in relevant molecular subsets of metastatic urothelial cancer” [1] by Dr. Sumanta Pal and colleagues, “Impact of Tumor Mutation Burden on Nivolumab Efficacy in Second-Line Urothelial Carcinoma Patients: Exploratory Analysis of the Phase II CheckMate 275 Study” [2] by Dr. Matthew Galsky and colleagues, and a second abstract by Dr. Galsky and his group “Epithelial-mesenchymal transition, T cell infiltration, and outcomes with nivolumab in urothelial cancer” [3].

ESMO 2017: Biological assessment of viable germ cell tumor in patients with seminoma and non-seminoma using miR371

Madrid, Spain (UroToday.com) Dr. Nappi from British Columbia, Canada and colleagues presented results of their biological assessment of viable germ cell tumor (GCT) using miR371 at today’s poster session at ESMO 2017. The pathological constitution of residual nodes after chemotherapy or of the borderline enlarged retroperitoneal lymph nodes in clinical stage I (CSI) GCT patients on surveillance is challenging, especially in tumor markers negative patients. Currently, accurate assessment requires pathological confirmation with RPLND or clinical follow-up to establish a pattern of growth. A plasma-based biomarker approach to identify patients with viable tumor would be uniquely valuable.

ESMO 2017: Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma: Real world data from an Italian Expanded Access Program

Madrid, Spain (UroToday.com)At ESMO 2017 in Madrid Spain, Dr. Procopio and colleagues from Italy presented data from the Italian Expanded Access Program (EAP) for using cabozantinib for metastatic renal cell carcinoma (mRCC). The results of the randomized phase III METEOR trial confirmed a survival benefit of cabozantinib over everolimus in patients with advanced clear-cell renal cell carcinoma who progressed after at least one previous antiangiogenic inhibitor [1]. The objective of the current study was to assess results from the Italian EAP for the treatment of mRCC with cabozantinib in real world clinical practice.

ESMO 2017: SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib in metastatic renal cell carcinoma

Madrid, Spain (UroToday.com) Dr. Pérez-Valderrama and Spanish colleagues presented their results of the IMDC validation for targeted therapies as second-line after first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC) at the ESMO 2017 poster session. Only 2% of patients included in the IMDC prognostic model for second-line targeted agents for mRCC had received first-line pazopanib [1]. The objective of this study was to validate the IMDC model for this population of patients receiving first-line pazopanib.

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide

Madrid, Spain (UroToday.com) Antoine Thiery-Vuillemin presented initial results from a patient reported outcomes (PROs) study among men receiving either abiraterone + prednisone or enzalutamide. For mCRPC patients prior to chemotherapy, both abiraterone + prednisone [1] and enzalutamide [2] have demonstrated improved overall survival (OS) compared to placebo.

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial

Madrid, Spain (UroToday.com) Dr. Andrén and colleagues from Sweden presented results of their clinical trial assessing cabazitaxel followed by ADT among men with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) at today’s poster session at ESMO 2017 in Madrid, Spain. Patients with newly diagnosed mHSPC have a poor prognosis with a 3-year overall survival (OS) rate of 50%.

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC)

Madrid, Spain (UroToday.com) Dr. Eisenberger and colleagues presented health-related quality of life (HRQL) results comparing reduced dose cabazitaxel to standard dose cabazitaxel in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) at today’s ESMO 2017 poster session. PROSELICA was a phase III study assessing the effect of cabazitaxel 20 mg/m2 vs cabazitaxel 25 mg/m2 on overall survival (OS) in a non-inferiority study of patients with mCRPC [1].

ESMO 2017: Outcomes of patients with metastatic renal cell carcinoma who were treated with second-line vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line immune checkpoint inhibitor therapy

Madrid, Spain (UroToday.com) Dr. Shah and colleagues from the MD Anderson Cancer Center presented their results of metastatic renal cell carcinoma (mRCC) patients receiving VEGFR-TKI therapy after first-line immune checkpoint inhibitor therapy at today’s poster session at ESMO 2017. Immune checkpoint inhibitor therapy is an established strategy in mRCC after progressive disease on VEGFR-TKI, however little data exists in the reverse sequence on response rate, progression-free survival (PFS), safety, and tolerability of TKI after first-line immune checkpoint inhibitor therapy.

ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma

Madrid, Spain (UroToday.com) Dr. Bergerot and colleagues presented their study assessing biopsychosocial distress and overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC). Previous studies have found that depressive symptoms are associated with poorer OS in patients with mRCC [1]. In other malignancies, biopsychosocial distress has also been linked to poorer OS, but in mRCC, this association is unclear. The objective of this study was to perform a single institutional assessment of rates and types of distress and evaluating the association between distress and OS.

ESMO 2017: SPAZO2 (SOGUG): Comparative effectiveness of everolimus vs axitinib as second-line after first-line pazopanib in metastatic renal carcinoma

Madrid, Spain (UroToday.com) Dr. Jose Angel Arranz Arija and Spanish colleagues presented their results of everolimus vs axitinib as second-line therapy after first-line pazopanib for patients with metastatic renal cell carcinoma (mRCC) at today’s poster session at ESMO 2017. Pivotal studies assessing axitinib [1] and everolimus [2] in the second-line for mRCC did not include patients treated with first-line pazopanib. In addition, everolimus vs axitinib have not been directly compared in clinical trials in this setting. The authors aimed to compare the effectiveness of everolimus vs axitinib in real world clinical practice, as second-line after pazopanib in mRCC.

ESMO 2017: Do patients with advanced nonseminomatous germ cell tumors and unfavorable time to normalization of tumor markers benefit with prolongation of 1-st line chemotherapy?

Madrid, Spain (UroToday.com) At the afternoon poster session at ESMO 2017, Dr. Tryakin and colleagues from Russia presented findings from their study assessing whether patients with advanced nonseminomatous germ cell tumors (NSGCT) and unfavorable time to normalization of tumor markers would benefit from prolongation of first-line chemotherapy. Three-four cycles of BEP chemotherapy are commonly recognized as a standard first-line treatment in advanced NSGCT.